RIGL
Price
$47.89
Change
-$0.24 (-0.50%)
Updated
Sep 24 closing price
Capitalization
899.06M
46 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$58.29
Change
+$0.64 (+1.11%)
Updated
Sep 24 closing price
Capitalization
25.67B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RIGL vs RPRX

RIGL vs RPRX Comparison Chart in %
View a ticker or compare two or three
VS
RIGL vs. RPRX commentary
Sep 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RIGL is a Buy and RPRX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
RIGL vs RPRX: Fundamental Ratings
RIGL
RPRX
OUTLOOK RATING
1..100
3033
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
7935
SMR RATING
1..100
1296
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
957
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for RIGL (45) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than RIGL’s over the last 12 months.

RPRX's Profit vs Risk Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for RIGL (79) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for RPRX (96) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew significantly faster than RPRX’s over the last 12 months.

RIGL's Price Growth Rating (37) in the Biotechnology industry is in the same range as RPRX (41) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's P/E Growth Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for RIGL (95) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RIGLRPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
48%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
47%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
42%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
57%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 14 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
61%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
65%
COMPARISON
Comparison
Sep 25, 2026
Stock price -- (RIGL: $48.13 vs. RPRX: $57.65)
Brand notoriety: RIGL and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RIGL: 53% vs. RPRX: 84%
Market capitalization -- RIGL: $899.06M vs. RPRX: $25.67B
RIGL [@Biotechnology] is valued at $899.06M. RPRX’s [@Biotechnology] market capitalization is $25.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RIGL’s FA Score shows that 1 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s).

  • RIGL’s FA Score: 1 green, 4 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, RPRX is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RIGL’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 4 bullish TA indicator(s).

  • RIGL’s TA Score: 4 bullish, 4 bearish.
  • RPRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both RIGL and RPRX are a good buy in the short-term.

Price Growth

RIGL (@Biotechnology) experienced а +8.21% price change this week, while RPRX (@Biotechnology) price change was -1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.84%. For the same industry, the average monthly price growth was -10.68%, and the average quarterly price growth was +8.45%.

Reported Earning Dates

RIGL is expected to report earnings on Nov 10, 2026.

RPRX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RIGL
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CHRW149.670.11
+0.07%
C.H. Robinson Worldwide
LUD4.18N/A
N/A
Luda Technology Group Ltd
PENG53.88-2.70
-4.77%
Penguin Solutions Inc
BMM5.26-0.51
-8.92%
Blue Moon Metals Inc.
TRNR2.59-0.40
-13.38%
Interactive Strength Inc.

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
-1.49%
AXON - RPRX
48%
Loosely correlated
-1.90%
INCY - RPRX
45%
Loosely correlated
-1.80%
VRTX - RPRX
42%
Loosely correlated
+0.26%
RIGL - RPRX
40%
Loosely correlated
-1.41%
EXEL - RPRX
37%
Loosely correlated
-2.44%
More